Table 1.

Beverage intake by cohort study in the pancreatic cancer analysis of the Pooling Project of Prospective Studies of Diet and Cancer

Median intake (interquartile range, g/d) among drinkersc, d
SexCohortaFollow-up yearsBaseline cohort sizebNumber of casesAge range, y% coffee drinkersCoffee% tea drinkersTea% SSB drinkerseSSB
FemaleBCDDP1987–199943,16210240–933947.1 (16.5–141.1)
CNBSS1980–200049,65410540–5985448.0 (224.0–896.0)77336.0 (128.0–672.0)3732.0 (14.7–64.0)
CPS II1992–200174,13816450–743628.9 (13.5–105.9)
CTS1995–200397,94511422–1043449.7 (18.1–159.5)
IWHS1986–200133,84416655–6990596.5 (292.7–1,065.6)58101.8 (18.9–236.8)4358.4 (29.8–159.1)
MCCS1990–200322,8303540–6985475.0 (190.0–475.0)86500.0 (200.0–900.0)4122.4 (11.2–68.8)
NLCS1986–199962,57312255–6996500.0 (375.0–625.0)89375.0 (250.0–500.0)4728.8 (14.4–68.8)
NYSC1980–198722,5504815–10785473.6 (473.6–710.4)51473.6 (236.8–473.6)
NHSb1986–200264,42516840–6574592.0 (236.8–592.0)63101.8 (33.2–236.8)3851.8 (29.6–159.1)
PLCO1993–200428,3156055–7485842.0 (337.1–842.8)85140.8 (21.6–328.6)6522.2 (5.54–48.2)
SMC1997–200436,6305449–8394492.0 (328.0–708.0)52222.0 (95.1–444.0)42112.0 (56.0–214.0)
MaleATBC1984–199926,98720450–6998600.0 (440.0–770.0)36157.1 (48.6–220.0)4247.1 (22.7–94.3)
CPS II1992–200166,16521050–745577.1 (20.0–141.4)
COSM1998–200545,3387545–7994636.0 (424.0–908.6)46273.4 (119.2–507.6)50283.0 (110.3–514.7)
HPFS1986–200245,87420540–7583592.0 (236.8–694.2)58101.8 (18.9–236.8)5688.2 (51.8–211.8)
MCCS1990–200314,9082840–6989500.0 (200.0–500.0)81500.0 (156.0–514.0)5728.0 (14.0–86.0)
NLCS1986–199958,27914555–6997500.0 (500.0–750.0)84375.0 (250.0–500.0)5349.9 (14.4–112.2)
NYSC1980–198730,3639015–10788710.4 (473.6–947.2)36236.8 (236.8–473.6)
PLCO1993–200429,9149055–7490874.5 (349.8–1,574.2)8143.5 (5.51–283.6)8249.2 (5.7–147.6)
Total853,8942,185
  • aATBC, Alpha-Tocopherol Beta-Carotene Cancer Prevention Study; BCDDP, Breast Cancer Detection Demonstration Project Follow-up Study; CNBSS, Canadian National Breast Screening Study; CPS II, Cancer Prevention Study II Nutrition Cohort; CTS, California Teachers Study; COSM, Cohort of Swedish Men; HPFS, Health Professionals Follow-up Study; IWHS, Iowa Women's Health Study; MCCS, Melbourne Collaborative Cohort Study; NLCS, The Netherlands Cohort Study; NYSC, New York State Cohort; NHS, Nurses' Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SMC, Swedish Mammography Cohort.

  • bCohort size is determined after applying study-specific exclusion criteria and further excluding participants with energy intakes beyond 3 SDs of their loge-transformed study-specific mean energy intake, history of cancer diagnosis at baseline (except for nonmelanoma skin cancer), and missing values for coffee, tea, and SSB intake (if the beverage was measured in the study); the CNBSS and the NLCS were analyzed as case–cohort studies and the above exclusions were not applied to their baseline cohort size; total cohort size = 853,894; total number of incident pancreatic cancer cases was 2,185.

  • c(‡) Intake of the particular beverage was not assessed or was not assessed as a separate item (e.g., coffee and tea were included as a single line item in their dietary assessment tool).

  • dFor coffee and tea, 8 oz. weighs approximately 237 g; for sugar-sweetened carbonated soft drinks, 12 oz. weighs approximately 355g.

  • eSugar-sweetened carbonated soft drink is abbreviated as SSB.